Global Messenger RNA Vaccines and Therapeutics Market Growth (Status and Outlook) 2025-2031

The global Messenger RNA Vaccines and Therapeutics market size is predicted to grow from US$ 14620 million in 2025 to US$ 30550 million in 2031; it is expected to grow at a CAGR of 13.1% from 2025 to 2031.

An mRNA vaccine is a vaccine that uses a molecular copy of messenger RNA to generate an immune response. [1] Such vaccines deliver antigen-coding mRNA molecules into immune cells, which use the designed mRNA as a template to build foreign proteins normally produced by pathogens such as viruses or cancer cells. These protein molecules stimulate an adaptive immune response, teaching the body to recognize and destroy the corresponding pathogen or cancer cell. mRNA is composed of RNA encapsulated in lipid nanoparticles, which protect the RNA strand and facilitate its uptake into cells. Reactogenicity, the propensity of the vaccine to produce adverse reactions, was similar to that of traditional non-RNA vaccines. People prone to autoimmune reactions may experience adverse reactions to messenger RNA vaccines. Compared with traditional vaccines, mRNA vaccines have the advantages of being easy to design, fast in production, low in cost, capable of inducing cellular and humoral immunity, and not interacting with genomic DNA.

United States market for Messenger RNA Vaccines and Therapeutics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Messenger RNA Vaccines and Therapeutics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Messenger RNA Vaccines and Therapeutics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Messenger RNA Vaccines and Therapeutics players cover BioNTech, Moderna, CureVac, Pfizer, Glaxo Smith Kline's, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Messenger RNA Vaccines and Therapeutics Industry Forecast” looks at past sales and reviews total world Messenger RNA Vaccines and Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Messenger RNA Vaccines and Therapeutics sales for 2025 through 2031. With Messenger RNA Vaccines and Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Messenger RNA Vaccines and Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Messenger RNA Vaccines and Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Messenger RNA Vaccines and Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Messenger RNA Vaccines and Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Messenger RNA Vaccines and Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Messenger RNA Vaccines and Therapeutics.

This report presents a comprehensive overview, market shares, and growth opportunities of Messenger RNA Vaccines and Therapeutics market by product type, application, key players and key regions and countries.

Segmentation by Type:
Self-amplifying
Conventional Non-amplifying

Segmentation by Application:
Cancer
Infectious Diseases
Autoimmune Diseases
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
BioNTech
Moderna
CureVac
Pfizer
Glaxo Smith Kline's
Daiichi Sankyo Company
Intellia Therapeutics
Arcturus Therapeutics
Emmy Vaccine
CSPC
CanSino
Fosun Pharma

Please note: The report will take approximately 2 business days to prepare and deliver. Show more